Kezar Life Sciences climbs after FDA lifts clinical hold on liver disease drug

Kezar Life Sciences

15/07/2025 22:11

** Shares of drug developer Kezar Life Sciences KZR.O rise 4.3% to $4.82 in extended trading

** The U.S. FDA has lifted a partial clinical hold on company's mid-stage trial of evaluating zetomipzomib for the treatment of autoimmune hepatitis, a rare chronic liver disease

** Zetomipzomib is a first-in-class selective immunoproteasome inhibitor designed to reduce inflammation without suppressing the immune system

** Kezar has shifted its focus to autoimmune hepatitis after suspending development of zetomipzomib in lupus nephritis — a condition that causes inflammation and damage in the kidneys due to a form of immune-related condition called lupus

** Company also exploring options to lift a clinical hold on zetomipzomib in lupus nephritis, based on recommendations from an independent committee

** Shares down 31% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))